Total amount: € 0,00
Oftalmologia Oggi Onlus c/o MVM Microchirurgia Villa Massimo, Roma, Italia
AIM: At present there is no established therapy for treatment of atrophic retinal forms that are often the end stage of many retinal diseases. In the context of Low Dose Medicine numerous molecules in various formulations, potentially useful for regenerative therapy of these pathological forms, are available. The purpose of this observational retrospective study was to test the improvement of the starting clinical condition after therapy with ability of drugs administered by injective or sublingual routes in order to promote the regenerative phase of retinal horizontal cells.
METHODS: Patients aged between 18 and 70 years were evaluated. All subjects showed a severe form of retinal atrophy, central or peripheral, documented with optical coherence tomography. Within the analized population some subgroups were defined for hereditary neurodegenerative diseases with atrophic evolution. Microperimetry (MP1 Nidek’s) and the electrorethinogram ISCEV standard were performed for both diagnosis and collected data evaluation.
RESULTS: Statistical analysis of the results has allowed us to highlight the considerable statistical significance of response increases obtained after therapy.
CONCLUSION: To date treatments with low dose drugs constitute the most promising therapeutic strategy for retinal regeneration after retinal atrophy.